Piperacillin-Tazobactam
- Generic Name
- Piperacillin-Tazobactam
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
适用于产β内酰胺酶而对哌拉西林耐药、但对本品敏感的细菌（如大肠埃希菌、克雷伯菌属、柠檬酸杆菌属、肠杆菌属、沙雷菌属、变形杆菌属、摩根菌属、雷极普罗维登菌、铜绿假单胞菌、流感嗜血杆菌、不动杆菌属、葡萄球菌属和拟杆菌属等）所致的下列中、重度感染：
1.肺炎、肺脓肿、脓胸、支气管扩张合并感染和慢性阻塞性肺病继发性感染等下呼吸道感染；
2.创伤或外科伤口继发皮肤软组织感染、蜂窝织炎、皮肤脓肿、糖尿病足感染；
3.胆囊炎、胆管炎、肝脓肿和腹膜炎等腹腔感染；
4.盆腔炎、子宫内膜炎、子宫周围炎、附件炎、盆腔脓肿等生殖系统感染；
5.单纯或复杂性尿路感染。本品用于铜绿假单胞菌严重感染时，应联合氨基糖苷类等其他抗铜绿假单胞菌的药物。
- Associated Conditions
- -
- Associated Therapies
- -
Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock
- Conditions
- Early Phase of Severe Sepsis and Septic Shock
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Sutep Jaruratanasirikul
- Target Recruit Count
- 50
- Registration Number
- NCT02730624
- Locations
- 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand
Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- St. Justine's Hospital
- Target Recruit Count
- 141
- Registration Number
- NCT02466438
- Locations
- 🇨🇦
St. Justine's Hospital, Montreal, Quebec, Canada
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
- Conditions
- Acute PyelonephritisUrinary Tract Infection Complicated
- Interventions
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- Melinta Therapeutics, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT02166476
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Phillip Brian Smith
- Target Recruit Count
- 32
- Registration Number
- NCT00873327
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸Wesley Medical Center, Wichita, Kansas, United States
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
- Conditions
- Hematological MalignancyLeukemiaMyelodysplasiaLymphomaMyelomaStem Cell Transplantation
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-11-16
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 801
- Registration Number
- NCT00195533
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
- Conditions
- Gram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella Infections
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-03-15
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00167999
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
- Conditions
- Bone Marrow SuppressionFever, Sweats, and Hot FlashesInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-16
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 859
- Registration Number
- NCT00003805
- Locations
- 🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇨🇭Universitaetsspital, Zurich, Switzerland
🇨🇭Ospedale San Giovanni, Bellinzona, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.